Thomas Weisel Upgrades Genentech to 'Buy'

Analyst Patrick Mooney says better-than-expected profit from Rixutan will help the company to develop four other key drugs in its pipeline

Thomas Weisel upgraded Genentech (DNA ) to buy from attractive.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.